News in brief: Antihistamines may enhance response to cancer immunotherapy; SCLC insights clear path to personalised medicine; 3 oncology drugs among most expensive for PBS

Antihistamines may enhance response to cancer immunotherapy Cancer patients on immunotherapy could see added efficacy and survival benefits with concurrent H1-antihistamines, a new study suggests. The study of 2,864 cancer patients on immuno- or chemotherapy with or without antihistamines found that anti-PD-1/PD-L1-treated lung cancer and melanoma patients on antihistamines had significantly improved survival over those ...

Already a member?

Login to keep reading.

© 2022 the limbic